ArriVent BioPharma (AVBP) Interest & Investment Income (2023 - 2026)

ArriVent BioPharma has disclosed Interest & Investment Income across 4 years of filings, most recently posting $2.8 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $2.8 million, up 17.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.6 million (down 10.16% YoY), and the FY2025 annual result was $11.2 million, down 18.77% from the prior year.
• Interest & Investment Income came in at $2.8 million for Q1 2026 at ArriVent BioPharma, down from $3.3 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $3.8 million in Q2 2024 to a low of $1.0 million in Q2 2023.
• The 4-year median for Interest & Investment Income is $2.9 million (2024), against an average of $2.8 million.
• Across the five-year window, Interest & Investment Income jumped 275.91% in 2024 and tumbled 41.83% in 2025, its largest moves.
• ArriVent BioPharma's Interest & Investment Income stood at $1.9 million in 2023, then surged by 59.58% to $3.1 million in 2024, then increased by 6.74% to $3.3 million in 2025, then retreated by 14.88% to $2.8 million in 2026.
• The last three Interest & Investment Income figures came in at $2.8 million (Q1 2026), $3.3 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.